

Summarizing Experiences with Site Enrollment in NCORP Cancer Care Delivery Research Studies

NCORP SENSE Project



A program of the National Cancer Institute
of the National Institutes of Health

NCORP SENSE Project - Rationale

- Robust cancer care delivery research (CCDR) portfolio
 - 19 CCDR studies approved
 - ~2/3 assessing clinician and/or organizational characteristics
 - 10 cluster RCTs
- Challenges
 - Delays in activating studies
 - Compliance with protocol efficiency guidelines
 - Site representativeness of participating sites
- The Need
 - Understand effective strategies used by NCORP Research Bases to increase site enrollment on CCDR studies

Qualitative Assessment with NCORP Research Base Staff

Purpose:

- Obtain feedback on effective strategies used by NCORP RBs regarding RB site enrollment experiences to cancer care delivery research (CCDR) studies
- Identify best practices/lessons learned to expedite time to study activation and enhance site representativeness

Method:

- Select one CCDR protocol for each Research Base (see Table 1)
- For each protocol, conduct interviews (30-45 min) with key staff involved in study development, implementation, and coordination/operations (n=28-35)
- Key staff are CCDR Subcommittee Chairs/Co-Chairs, Study Chairs/Investigators, Study Coordinators, Operations Leads, and others as appropriate

Selected NCORP CCDR Protocols by Research Base (n=7)

Table 1.

Research Base	CCDR Protocol
Alliance	A231601CD: Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
NRG	NRG-CC007CD: Optimizing Survivorship Care Plans for Prostate Cancer Survivors who Receive Androgen Deprivation Therapy
ECOG-ACRIN	EAQ171CD Smokefree – Implementing Virtual Tobacco Treatment in Community Oncology Practices (Smoke Free 2.0)
COG	ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in AYA Acute Lymphoblastic Leukemia
SWOG	A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
URCC	URCC-18004CD: Understanding the Impact of Drug Shortages on Oncology Care Delivery
Wake Forest	WF20817CD: Implementation of Smoking Cessation Services within NCORP Community Sites with Organized Lung Cancer Screening Programs (OaSiS)

Next Steps

- Email from Westat, Inc to schedule interviews
 - Directly to Research Base PIs and Study Co-Chairs
 - From: Melanie Chansky or Sophia Tsakraklides
- NCI Lead
 - Brenda Adjei (Brenda.Adjei@nih.gov) with any questions or concerns